Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption
DJ Colby, M Sarnecki, DH Barouch, S Tipsuk… - Nature Medicine, 2020 - nature.com
DJ Colby, M Sarnecki, DH Barouch, S Tipsuk, DJ Stieh, E Kroon, A Schuetz, J Intasan…
Nature Medicine, 2020•nature.comWe administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens
or placebo in 26 individuals who initiated antiretroviral therapy during acute human
immunodeficiency virus infection as an exploratory study to determine the safety and
duration of viremic control after treatment interruption. The vaccine was safe and generated
robust immune responses, but delayed time to viral rebound compared to that in placebo
recipients by only several days and did not lead to viremic control after treatment interruption …
or placebo in 26 individuals who initiated antiretroviral therapy during acute human
immunodeficiency virus infection as an exploratory study to determine the safety and
duration of viremic control after treatment interruption. The vaccine was safe and generated
robust immune responses, but delayed time to viral rebound compared to that in placebo
recipients by only several days and did not lead to viremic control after treatment interruption …
Abstract
We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).
nature.com
